24 related articles for article (PubMed ID: 8580366)
1. Anti-interleukin 1alpha autoantibodies.
Miossec P
Ann Rheum Dis; 2002 Jul; 61(7):577-9. PubMed ID: 12079894
[No Abstract] [Full Text] [Related]
2. Hemolytically active (acylated) alpha-hemolysin elicits interleukin-1beta (IL-1beta) but augments the lethality of Escherichia coli by an IL-1- and tumor necrosis factor-independent mechanism.
Gleason TG; Houlgrave CW; May AK; Crabtree TD; Sawyer RG; Denham W; Norman JG; Pruett TL
Infect Immun; 1998 Sep; 66(9):4215-21. PubMed ID: 9712770
[TBL] [Abstract][Full Text] [Related]
3. Regulation of brain interleukin-1 beta (IL-1 beta) system mRNAs in response to pathophysiological concentrations of IL-1 beta in the cerebrospinal fluid.
Ilyin SE; Sonti G; Gayle D; Plata-Salamán CR
J Mol Neurosci; 1996; 7(3):169-81. PubMed ID: 8906613
[TBL] [Abstract][Full Text] [Related]
4. Cachexia and the acute-phase protein response in inflammation are regulated by interleukin-6.
Oldenburg HS; Rogy MA; Lazarus DD; Van Zee KJ; Keeler BP; Chizzonite RA; Lowry SF; Moldawer LL
Eur J Immunol; 1993 Aug; 23(8):1889-94. PubMed ID: 8344351
[TBL] [Abstract][Full Text] [Related]
5. Interleukin 6, but not ciliary neurotrophic factor or leukaemia inhibitory factor, is responsible for the acute phase response to turpentine-induced myositis.
Kaibara A; Espat NJ; Auffenberg T; Abouhamze AS; Martin D; Kalra S; Moldawer LL
Cytokine; 1998 Jun; 10(6):452-6. PubMed ID: 9632532
[TBL] [Abstract][Full Text] [Related]
6. Interleukin 1 receptor blockade attenuates the host inflammatory response.
Gershenwald JE; Fong YM; Fahey TJ; Calvano SE; Chizzonite R; Kilian PL; Lowry SF; Moldawer LL
Proc Natl Acad Sci U S A; 1990 Jul; 87(13):4966-70. PubMed ID: 1695006
[TBL] [Abstract][Full Text] [Related]
7. Failure of IL-1 receptor antagonist and monoclonal anti-IL-1 receptor antibody to inhibit antigen-specific immune responses in vivo.
Faherty DA; Claudy V; Plocinski JM; Kaffka K; Kilian P; Thompson RC; Benjamin WR
J Immunol; 1992 Feb; 148(3):766-71. PubMed ID: 1530956
[TBL] [Abstract][Full Text] [Related]
8. Preferential localization of systemically administered radiolabeled interleukin 1alpha in experimental inflammation in mice by binding to the type II receptor.
van der Laken CJ; Boerman OC; Oyen WJ; van de Ven MT; Chizzonite R; Corstens FH; van der Meer JW
J Clin Invest; 1997 Dec; 100(12):2970-6. PubMed ID: 9399942
[TBL] [Abstract][Full Text] [Related]
9. Interleukin 1 binding to its type I, but not type II receptor, modulates the in vivo acute phase response.
Oldenburg HS; Pruitt JH; Lazarus DD; Rogy MA; Chizzonite R; Lowry SF; Moldawer LL
Cytokine; 1995 Aug; 7(6):510-6. PubMed ID: 8580366
[TBL] [Abstract][Full Text] [Related]
10. Characterization of mouse IL-1 receptors: evidence for IL-1 receptor heterogeneity.
Kilian PL; Stern AS; Gubler U; Chizzonite RA
Prog Clin Biol Res; 1990; 349():251-7. PubMed ID: 2144638
[No Abstract] [Full Text] [Related]
11. The type II 'decoy' receptor: a novel regulatory pathway for interleukin 1.
Colotta F; Dower SK; Sims JE; Mantovani A
Immunol Today; 1994 Dec; 15(12):562-6. PubMed ID: 7848516
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
